Minute Insight: OxfordVR’s Virtual Reality Program Treats Agoraphobia In Trial

Results of a 346-patient randomized trial run by the UK’s National Health Service showed the automated virtual reality system developed by researchers at Oxford University helped people with agoraphobia re-engage with day-to-day activities outside their home.

Minute Insight
• Source: Informa/Alamy

Virtual reality (VR) simulations can help housebound people who are extremely anxious going outside to re-engage with the world outside without distress.

OxfordVR, an University of Oxford “spinout company” founded in 2018, has developed gameChange, a VR program to help people overcome...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Minute Insights

Minute Insight: Haemonetics Buys OpSens To Add Fiber-Optic Sensors For Intervention

 
• By 

Haemonetics will acquire Quebec-based OpSens for CAD $2.90 per share, or about US $253m at current exchange rates. Haemonetics expects OpSens' fiber-optic technology to complement its interventional cardiology portfolio.

Minute Insight: Best Buy Will Sell Dexcom CGM

 
• By 

The retail giant will sell the Dexcom G7 continuous glucose monitoring system to eligible customers through a new online platform.

Minute Insight: Stimdia Starts Trial Of Phrenic Nerve Stimulator For Patients On Ventilators

 

Stimdia is trying to restore respiratory function in ICU patients with phrenic nerve stimulation.

Minute Insight: Medtronic May Sell Respiratory And Monitoring Units To Private Equity

 
• By 

Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.

More from Medtech Insight

Abbott Lowers Outlook But Headwinds Are Temporary

 

Despite headwinds, executives remain optimistic about growth in Abbott’s medical devices and diabetes divisions and plan several product rollouts, including the Volt PFA catheter for electrophysiology and the dual glucose-ketone sensor CGM.

A Passport To Streamlined Medtech Access Under UK Life Sciences Plan

 
• By 

An “NHS Innovator Passport” that allows quicker uptake of proven technologies across the national healthcare provider is one of the wins the UK government is looking to score from its new Life Sciences Sector plan. The plan majors on prevention. The medtech industry has given it a cautious welcome.

Device Sterilization Plants Get Extra 2 Years To Comply On EtO Phase-Out

 
• By 

The exemption, which President Donald Trump announced on July 17, is intended to cut the risk of critical device shortages. Stakeholders say the technology needed to cut emissions to required levels is not yet widely available.